Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

Biotechnology

Healthcare
$0.37 -6.21%

-$0.10 today

Market cap
$69.21M
Beta
2.76
P/E (TTM)
-1.2
EPS (TTM)
-$1.24
52W Low $0.72High $3.65

Volume 1.50M

Average 2.02M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$241.16M

FY 2025 · Annual

Net Income

-$236.93M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00668K05M
Gross Profit00(668K)0(5M)
Gross Margin—————
Research & Development212.78M104.75M142.72M200.93M176.07M
Selling, General & Admin24.55M31.12M44.81M62.54M60.09M
Operating Expenses237.32M135.87M187.53M263.46M236.16M
Depreciation & Amortization538K594K668K631K208K
EBITDA(236.77M)(130.31M)(234.99M)(242.98M)(233.37M)
EBITDA Margin—————
Operating Income(237.32M)(135.87M)(188.19M)(263.46M)(241.16M)
Operating Margin—————
Interest Income04.56M16.61M19.93M8.34M
Interest Expense00003.22M
Other Income / Expenses11K4.97M(47.46M)19.86M4.36M
Income Before Tax(237.31M)(130.9M)(235.66M)(243.61M)(236.8M)
Pre-Tax Margin—————
Income Tax Expense00268K178K130K
Net Income(237.31M)(130.9M)(235.93M)(243.79M)(236.93M)
Net Margin—————
EPS (Basic)(1.56)(0.86)(1.49)(1.53)(1.45)
EPS (Diluted)(1.56)(0.86)(1.49)(1.53)(1.45)
Weighted Avg Shares151.95M151.95M158.83M159.38M163.39M
Weighted Avg Shares (Diluted)151.95M151.95M158.83M159.38M163.39M

NMRA Earnings Waterfall · TTM

NASDAQ:NMRA · Revenue to Net Income

Key Ratios

EPS$-1.33
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.2
P/S Ratio0.0

Analysis

$0 of revenue converted into -$222.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.33, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportOct 30, 2026
4Statement of changes in beneficial ownershipAug 21, 2026
4Statement of changes in beneficial ownershipAug 21, 2026
4Statement of changes in beneficial ownershipAug 21, 2026
4Statement of changes in beneficial ownershipAug 21, 2026

How much revenue does NMRA generate?

Neumora Therapeutics, Inc. Common Stock (NMRA) reported $0.00 of revenue in fiscal 2025.

Is NMRA profitable?

Neumora Therapeutics, Inc. Common Stock (NMRA) reported -$236.93M of net income.